The Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan has been awarded a $24 million grant ...
This is Uganda's sixth outbreak of Ebola Sudan, which causes severe hemorrhagic fever disease with a case fatality rate of up to 50%. No licensed vaccines or therapeutics are available for Ebola Sudan ...
Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...
Star Phoenix on MSN6d
VIDO aims to create 'holy grail' of vaccines with global research grant“The clever design works by presenting fragments of several coronaviruses together to potentially induce a strong immune ...
allAfrica.com on MSN12h
Uganda: WHO and Partners Enable Access to Candidate Vaccine and Treatments for Outbreak of Sudan Ebola Virus Disease in UgandaWHO and partners have immediately boosted their support to the Ugandan government's response to an outbreak of Sudan virus disease outbreak (SVD, part of the Ebola family), including by facilitating ...
San Francisco confirmed that a child in the city became the first case of H5N1. A panel of biotech leaders discussed what ...
VIDO's funding flows from Norwegian-based Coalition for Epidemic Preparedness Innovations (CEPI) into its ongoing development of its pan-sarbecovirus vaccine. Dr. Nicole Lurie, Executive Director ...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot ...
Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback